ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2894

Triggering Receptor Expressed on Myeloid Cells 1 In Systemic Lupus Erythematosus

Laurie Davis1, Yong Du2, Tianfu Wu3 and Chandra Mohan4, 1Internal Medicine, UT Southwestern Medical Center, Dallas, TX, 2Internal Medicine - Rheumatic Diseases, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, 3Division of Rheumatology/Internal Medicine, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, 4University of Houston, Houston, TX

Meeting: ACR/ARHP Annual Meeting 2013

Keywords: Biomarkers, pathogenesis and renal disease, SLE

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: In healthy individuals, TREM-1 proteins are cell surface receptors expressed by hematopoietic cells of the myeloid lineage. TREM-1 is a potent amplifier of proinflammatory responses. TREM-2 acts to downregulate inflammatory cytokines and is associated with suppressive macrophages. In prior studies increased soluble TREM-1 (sTREM-1) levels in serum accurately correlated with sepsis. TREM-1 hyper-expression has been observed in auto-inflammatory responses, such as rheumatoid arthritis and inflammatory bowel disease. In both sepsis and arthritis models, TREM-1 inhibitors prevent tissue destruction caused by inflammation. We posit that TREM-1  plays a significant role in regulating SLE renal disease and that TREM-1 is involved in the amplification of the inflammatory response.

Methods: We have explored TREM-1 expression and function in a murine anti-glomerular basement membrane antibody-induced nephritis (anti-GBM) model which shares a number of relevant pathogenic features with lupus nephritis. Mice  were pre-sensitized on day -5 (5 days before induction of anti-GBM) with rabbit IgG (250 µg/mouse) in adjuvant. On day 0, the mice received anti-GBM serum; 200µg of total IgG in a 300µl volume intravenously per mouse. After induction of anti-GBM disease, urine was collected from 129/SvJ and B6 mice at different timepoints and sTREM-1 was assessed by ELISA. Renal disease was measured by proteinuria and renal pathology. The impact of a TREM-1 inhibitory peptide (LP17) was assessed.

Results: In the anti-GBM model, 129/SvJ mice developed severe GN, whereas B6 mice did not. Renal macrophages from 129/SvJ mice expressed elevated TREM-1 compared to B6 mice. Anti-GBM disease induced elevated urine sTREM-1 levels in 129/SvJ versus control B6 mice. After induction of anti-GBM disease, urine was collected from 129/SvJ and B6 mice at different timepoints and sTREM-1 was assessed by ELISA . Elevated sTREM-1  levels were detected in the urine of 129/SvJ mice from day 7 through day 21. In the anti-GBM model, TREM-1 blockade with an inhibitory peptide ameliorated renal inflammation compared to control peptide. TREM-1 blockade inhibited proteinuria, as well as renal disease as measured by GN class, severity of tubulo-interstitial disease, crescent formation, and inflammatory cell infiltrates. Elevated sTREM-1 levels were detected in serum of spontaneous murine lupus (SLN) models compared to controls and in SLN renal biopsies. Finally, elevated sTREM-1 levels were detected in serum of SLE patients with nephritis and TREM-1 was detected in renal biopsies from SLE patients but not controls.

Conclusion: These studies suggest that the TREM-1 hyper-expression in the nephritis prone 129/SvJ strain has critical pathogenic relevance, and that TREM-1 is amenable to therapeutic targeting for nephritis. These studies could have important implications in the understanding of pathogenic mechanisms driving SLE renal disease. More specific assays for nephritis, such as TREM-1 as a prognostic indicator of disease, might greatly enhance quality of therapeutic management for SLE nephritis.


Disclosure:

L. Davis,
None;

Y. Du,
None;

T. Wu,
None;

C. Mohan,
None.

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2013

ACR Meeting Abstracts - https://acrabstracts.org/abstract/triggering-receptor-expressed-on-myeloid-cells-1-in-systemic-lupus-erythematosus/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology